Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

927
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
927
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

752
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
752
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.5K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.5K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.4K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.4K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.6K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.6K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Manifestations of tuberculosis possibly associated with rituximab in a patient with diagnosed multiple sclerosis: a case report.

Journal of medical case reports·2026
Same author

Natural compounds targeting multidrug-resistant Acinetobacter baumannii: Anti-Biofilm, anti-resistance, and synergistic strategies.

Microbial pathogenesis·2026
Same author

Association of Myosteatosis and of Graft Loss after Kidney Transplantation: An International Observational Study.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Pre- and Post-Kidney Transplant Abdominal Computed Tomography-Based Muscle Measurements and Post-KT Outcomes.

Clinical transplantation·2025
Same author

Insufficient knowledge of Human Papillomavirus among reproductive-aged women from Arak, Iran.

BMC women's health·2025
Same author

A Dual-Branch Network with Mixed and Self-Supervision for Medical Image Segmentation: An Application to Segment Edematous Adipose Tissue.

Medical image learning with limited and noisy data : second international workshop, MILLanD 2023, held in conjunction with MICCAI 2023, Vancouver, BC, Canada, October 8, 2023, proceedings. MILLanD (Workshop) : (2nd : 2023 : Vancouver, B...·2025

Related Experiment Video

Updated: Apr 16, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Arginine adjunctive therapy in active tuberculosis.

Aliasghar Farazi1, Omid Shafaat2, Masoomeh Sofian1

  • 1Department of Infectious Disease, School of Medicine, Arak University of Medical Sciences, Arak 38159 34798, Iran ; Tuberculosis and Pediatric Infectious Diseases Research Center, Arak University of Medical Sciences, Arak 38159 34798, Iran.

Tuberculosis Research and Treatment
|March 4, 2015
PubMed
Summary

L-arginine supplementation improved outcomes in active tuberculosis patients. This dietary intervention reduced symptoms and increased body mass index, suggesting its utility as an adjunctive therapy.

More Related Videos

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
03:47

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

770
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K

Related Experiment Videos

Last Updated: Apr 16, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K
A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
03:47

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

770
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K

Area of Science:

  • Immunology
  • Nutritional Science
  • Infectious Diseases

Background:

  • Dietary supplementation is explored to enhance immune function.
  • L-arginine is investigated for its potential role in improving tuberculosis treatment outcomes.

Purpose of the Study:

  • To evaluate L-arginine as an adjunctive therapy for active pulmonary tuberculosis.
  • To assess the impact of L-arginine on treatment success, symptom improvement, and inflammatory markers.

Main Methods:

  • A randomized clinical trial involving 63 participants with smear-positive pulmonary tuberculosis.
  • Participants received either L-arginine or placebo for 4 weeks alongside conventional chemotherapy.
  • Outcomes included treatment success, sputum conversion, weight gain, clinical symptoms, ESR, CRP, and Hg levels.

Main Results:

  • L-arginine supplementation significantly reduced constitutional symptoms (P=0.032) and C-reactive protein (CRP) levels (P=0.03) after one month.
  • Patients receiving L-arginine showed significant increases in Body Mass Index (BMI) at both one and two months (P=0.032 and P=0.04).

Conclusions:

  • L-arginine serves as a beneficial adjunctive therapy for active tuberculosis.
  • Potential mechanisms include increased nitric oxide production, leading to improved constitutional symptoms and weight gain.